Evommune (NYSE:EVMN) was upgraded by analysts at Zacks Research to a "hold" rating.
Evommune (NYSE:EVMN) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.
Evommune (NYSE:EVMN) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
Evommune (NYSE:EVMN) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $42.00 price target on the stock.
Evommune (NYSE:EVMN) is now covered by analysts at Evercore ISI. They set an "outperform" rating on the stock.